August 2003 in “药物不良反应杂志” Combining finasteride and terazosin can cause severe allergic reactions.
18 citations
,
January 2024 in “Regenerative Biomaterials” The hydrogel helps heal diabetic wounds by reducing infection and inflammation.
203 citations
,
December 1947 in “Annals of Internal Medicine”
October 2019 in “European heart journal” Androgen-deprivation therapies increase the risk of certain heart conditions, but testosterone treatment may help.
September 2023 in “International Journal of Trichology” Tofacitinib helped a woman regrow hair with no major side effects.
9 citations
,
October 2021 in “International Journal of Dermatology” Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.
1 citations
,
July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.
March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
8 citations
,
February 2021 in “Journal of the American Heart Association” Medical castration in prostate cancer patients can increase the risk of serious heart rhythm problems, so it's important to monitor heart activity during treatment.
7 citations
,
August 2024 in “Clinical and Experimental Dermatology” Upadacitinib is effective and safe for treating severe alopecia areata in teens.
January 2024 in “http://isrctn.com/” Teak leaf extract hair tonic was tested for hair growth and safety.
April 2025 in “Vestnik dermatologii i venerologii” JAK inhibitors like tofacitinib are effective and safer for severe alopecia areata than glucocorticosteroids.
10 citations
,
June 2022 in “Frontiers in Immunology” Fucoidan reduces bone cell formation by affecting T-cell activity.
1 citations
,
June 2017 in “Journal of the American Academy of Dermatology” Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.
19 citations
,
January 1993 in “Dermatologic Clinics”
August 2019 in “Jurnal Biosains Pascasarjana” Acupuncture therapy significantly reduced hair loss in women aged 31-50 with female pattern hair loss.
December 1989 in “PubMed”
November 2020 in “Dubai medical journal” Tofacitinib may effectively regrow hair in alopecia totalis patients.
40 citations
,
December 2016 in “Journal of Dermatological Treatment” JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.
2 citations
,
August 2014 in “Journal of dermatological science” Adapalene 0.1% effectively reduces acne by decreasing comedones and altering skin properties.
October 2006 in “Urology” The study found that different criteria led to different patient groups in the CombAT study compared to the MTOPS study.
29 citations
,
October 2020 in “Environmental health perspectives” Five preservatives may disrupt hormone function and need more health and environmental risk assessment.
July 2025 in “Journal of Cosmetic Dermatology” Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.
2 citations
,
August 2017 in “Drug and therapeutics bulletin” Strontium ranelate is no longer available for treatment.
238 citations
,
November 2016 in “Journal of The American Academy of Dermatology” Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
May 2024 in “International journal of medicine and psychology.” Most young people in Vladivostok view COVID-19 vaccination positively but value personal freedom and have mixed feelings about restrictions and vaccine safety.
77 citations
,
January 1980 in “Carcinogenesis” TPA is about 50 times more effective at promoting tumors than MZ.
26 citations
,
January 2014 in “ALTEX” Pesticides can cause reproductive and adrenal health issues.
2 citations
,
May 2025 in “Archives of Dermatological Research” JAK inhibitors do not increase cancer risk in severe alopecia areata compared to traditional treatments.
19 citations
,
March 2022 in “Journal of Infection” Canakinumab's effect on COVID-19 outcomes is unclear.